Paradigm BiopharmaceuticalsASX:PAR 27 3-Year ROIIC % is 3,243.06 as of Jun. 2025, which is 164% above its 10-year median of 1,228.57. GuruFocus rates ASX:PAR with a GF Score™ of 27/100. The stock has 4 warning signs investors should review. Among 1,319 Biotechnology companies, Paradigm Biopharmaceuticals ranks better than 97.88% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Paradigm Biopharmaceuticals's 3-Year ROIIC % for the quarter that ended in Jun. 2025 was 3,243.06%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Paradigm Biopharmaceuticals's 3-Year ROIIC % or its related term are showing as below:
ASX:PAR's 3-Year ROIIC % is ranked better than 97.88% of 1319
companies
in the Biotechnology industry
Industry Median: -4.44
vs ASX:PAR: 3243.06
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Paradigm Biopharmaceuticals 3-Year ROIIC % Related Terms
Paradigm Biopharmaceuticals 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:PAR vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Paradigm Biopharmaceuticals's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paradigm Biopharmaceuticals 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Paradigm Biopharmaceuticals's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Paradigm Biopharmaceuticals's 3-Year ROIIC % falls into.
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -23.441 (Jun. 2025) - -47.991 (Jun. 2022) )
/
( 5.019 (Jun. 2025) - 4.262 (Jun. 2022) )
=
24.55
/
0.757
=
3,243.06%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Paradigm Biopharmaceuticals (ASX:PAR) has a 3-Year ROIIC % of 3,243.06 as of Jun. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Paradigm Biopharmaceuticals and its competitors. This is 164% above median its historical median of 1,228.57. Over the past decade, Paradigm Biopharmaceuticals' 3-Year ROIIC % has ranged from 148.92 to 38,935.05. According to the industry distribution chart, Paradigm Biopharmaceuticals ranks #28 out of 1319 companies in the Biotechnology industry, placing it in the top 2.1%.
Is Paradigm Biopharmaceuticals' 3-Year ROIIC % too high?
Paradigm Biopharmaceuticals' current 3-Year ROIIC % of 3,243.06 is 164% above median its 10-year median of 1,228.57. Over the past 10 years, this metric has ranged from a low of 148.92 to a high of 38,935.05. Based on the distribution chart, Paradigm Biopharmaceuticals ranks #28 out of 1319 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Paradigm Biopharmaceuticals has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Paradigm Biopharmaceuticals' 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Paradigm Biopharmaceuticals ranks #28 out of 1319 companies for 3-Year ROIIC %. This places Paradigm Biopharmaceuticals in the top 2% of its industry — outperforming the majority of peers. Historically, Paradigm Biopharmaceuticals' own 3-Year ROIIC % has ranged from 148.92 to 38,935.05 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Paradigm Biopharmaceuticals and its competitors. Paradigm Biopharmaceuticals's current 3-Year ROIIC % is 3,243.06, which is 164% above median its own 10-year median of 1,228.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paradigm Biopharmaceuticals stock overvalued right now?
Paradigm Biopharmaceuticals (ASX:PAR) has a current 3-Year ROIIC % of 3,243.06. The current 3-Year ROIIC % is 3,243.06, which is 164% above median its 10-year median of 1,228.57. Paradigm Biopharmaceuticals' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Paradigm Biopharmaceuticals (ASX:PAR), the current 3-Year ROIIC % is 3,243.06 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulfate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.
27GF Score
Get the complete analysis for ASX:PAR
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PAR has been successfully added to your 
